These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19001322)

  • 1. Physicians' experiences with BRCA1/2 testing in community settings.
    Keating NL; Stoeckert KA; Regan MM; DiGianni L; Garber JE
    J Clin Oncol; 2008 Dec; 26(35):5789-96. PubMed ID: 19001322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary care providers' willingness to recommend BRCA1/2 testing to adolescents.
    O'Neill SC; Peshkin BN; Luta G; Abraham A; Walker LR; Tercyak KP
    Fam Cancer; 2010 Mar; 9(1):43-50. PubMed ID: 19390990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management updates for women with a BRCA1 or BRCA2 mutation.
    Nusbaum R; Isaacs C
    Mol Diagn Ther; 2007; 11(3):133-44. PubMed ID: 17570734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
    Kurian AW; Ward KC; Hamilton AS; Deapen DM; Abrahamse P; Bondarenko I; Li Y; Hawley ST; Morrow M; Jagsi R; Katz SJ
    JAMA Oncol; 2018 Aug; 4(8):1066-1072. PubMed ID: 29801090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study.
    Nilsson MP; Nilsson ED; Borg Å; Brandberg Y; Silfverberg B; Loman N
    Breast Cancer Res Treat; 2019 Jan; 173(2):313-318. PubMed ID: 30311024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physicians' experience, practice and education, on genetic testing and genetic counseling: a nationwide survey study in Greece.
    Fountzilas E; Apostolou P; Vasiliadis AV; Aivazi D; Saloustros E; Fostira F
    Fam Cancer; 2022 Oct; 21(4):479-487. PubMed ID: 35067824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study.
    McCarthy AM; Bristol M; Fredricks T; Wilkins L; Roelfsema I; Liao K; Shea JA; Groeneveld P; Domchek SM; Armstrong K
    Cancer; 2013 Oct; 119(20):3596-603. PubMed ID: 23861169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline Genetic Testing: What the Breast Surgeon Needs to Know.
    Plichta JK; Sebastian ML; Smith LA; Menendez CS; Johnson AT; Bays SM; Euhus DM; Clifford EJ; Jalali M; Kurtzman SH; Taylor WA; Hughes KS
    Ann Surg Oncol; 2019 Jul; 26(7):2184-2190. PubMed ID: 30941656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1/2 test results impact risk management attitudes, intentions, and uptake.
    O'Neill SC; Valdimarsdottir HB; Demarco TA; Peshkin BN; Graves KD; Brown K; Hurley KE; Isaacs C; Hecker S; Schwartz MD
    Breast Cancer Res Treat; 2010 Dec; 124(3):755-64. PubMed ID: 20383578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary care physician referral practices regarding BRCA1/2 genetic counseling in a major health system.
    Linfield DT; Rothberg MB; Pfoh ER; Noss R; Cassard L; Powers JC; Lipold L; Martinez KA
    Breast Cancer Res Treat; 2022 Sep; 195(2):153-160. PubMed ID: 35842521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: a qualitative study of patient preferences.
    Hurley K; Rubin LR; Werner-Lin A; Sagi M; Kemel Y; Stern R; Phillips A; Cholst I; Kauff N; Offit K
    Cancer; 2012 Dec; 118(24):6270-7. PubMed ID: 22736296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International variation in physicians' attitudes towards prophylactic mastectomy - comparison between France, Germany, the Netherlands and the United Kingdom.
    Den Heijer M; van Asperen CJ; Harris H; Nippert I; Schmidtke J; Bouhnik AD; Julian-Reynier C; Evans DG; Tibben A
    Eur J Cancer; 2013 Sep; 49(13):2798-805. PubMed ID: 23692813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing.
    Kwong A; Chu AT
    Asian Pac J Cancer Prev; 2012; 13(5):2241-7. PubMed ID: 22901201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specialty Care and Counselling about Hereditary Cancer Risk Improves Adherence to Cancer Screening and Prevention in Newfoundland and Labrador Patients with
    Roebothan A; Smith KN; Seal M; Etchegary H; Dawson L
    Curr Oncol; 2023 Oct; 30(10):9367-9381. PubMed ID: 37887578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling.
    Metcalfe KA; Liede A; Hoodfar E; Scott A; Foulkes WD; Narod SA
    J Med Genet; 2000 Nov; 37(11):866-74. PubMed ID: 11073541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers.
    Dhar SU; Cooper HP; Wang T; Parks B; Staggs SA; Hilsenbeck S; Plon SE
    Breast Cancer Res Treat; 2011 Aug; 129(1):221-7. PubMed ID: 21465171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
    Kemp Z; Turnbull A; Yost S; Seal S; Mahamdallie S; Poyastro-Pearson E; Warren-Perry M; Eccleston A; Tan MM; Teo SH; Turner N; Strydom A; George A; Rahman N
    JAMA Netw Open; 2019 May; 2(5):e194428. PubMed ID: 31125106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
    Theobald KA; Susswein LR; Marshall ML; Roberts ME; Mester JL; Speyer D; Williams RNW; Knapke SC; Solomon SR; Murphy PD; Klein RT; Hruska KS; Solomon BD
    Ann Surg Oncol; 2018 Nov; 25(12):3556-3562. PubMed ID: 30167906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.